ArticleJournal of cheminformatics2022
MolData, a molecular benchmark for disease and target based machine learning.
Article in Journal of cheminformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- GPCRact: a hierarchical framework for predicting ligand-induced GPCR activity via allosteric communication modeling.Briefings in bioinformatics · 2026Article
- Learning Multidimensional Electronegativity of Selected Atom Types in Organic Molecules Using Graph Neural Networks.ACS omega · 2025Article
- A Benchmark Set of Bioactive Molecules for Diversity Analysis of Compound Libraries and Combinatorial Chemical Spaces.Journal of chemical information and modeling · 2025Article
- Artificial intelligence approaches for anti-addiction drug discovery.Digital discovery · 2025Review
- InertDB as a generative AI-expanded resource of biologically inactive small molecules from PubChem.Journal of cheminformatics · 2025Article
- Machine Learning-Enabled Drug-Induced Toxicity Prediction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Augmented BindingNet dataset for enhanced ligand binding pose predictions using deep learning.npj drug discovery · 2025Article
- Machine Learning-Driven Data Valuation for Optimizing High-Throughput Screening Pipelines.Journal of chemical information and modeling · 2024Article
- Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery.ACS central science · 2024Article
- Practical guidelines for the use of gradient boosting for molecular property prediction.Journal of cheminformatics · 2023Article
- Evaluating the Use of Graph Neural Networks and Transfer Learning for Oral Bioavailability Prediction.Journal of chemical information and modeling · 2023Article
- ProfhEX: AI-based platform for small molecules liability profiling.Journal of cheminformatics · 2023Article
- Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs.Molecules (Basel, Switzerland) · 2023Review
- Papyrus: a large-scale curated dataset aimed at bioactivity predictions.Journal of cheminformatics · 2023Article
- Redesigning plant specialized metabolism with supervised machine learning using publicly available reactome data.Computational and structural biotechnology journal · 2023Review
- Tuning gradient boosting for imbalanced bioassay modelling with custom loss functions.Journal of cheminformatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep learning's automatic feature extraction has been a revolutionary addition to computational drug discovery, infusing both the capabilities of learning abstract features and discovering complex molecular patterns via learning from molecular data. Since biological and chemical knowledge are necessary for overcoming the challenges of data curation, balancing, training, and evaluation, it is important for databases to contain information regarding the exact target and disease of each bioassay. The existing depositories such as PubChem or ChEMBL offer the screening data for millions of molecules against a variety of cells and targets, however, their bioassays contain complex biological descriptions which can hinder their usage by the machine learning community. In this work, a comprehensive disease and target-based dataset is collected from PubChem in order to facilitate and accelerate molecular machine learning for better drug discovery. MolData is one the largest efforts to date for democratizing the molecular machine learning, with roughly 170 million drug screening results from 1.4 million unique molecules assigned to specific diseases and targets. It also provides 30 unique categories of targets and diseases. Correlation analysis of the MolData bioassays unveils valuable information for drug repurposing for multiple diseases including cancer, metabolic disorders, and infectious diseases. Finally, we provide a benchmark of more than 30 models trained on each category using multitask learning. MolData aims to pave the way for computational drug discovery and accelerate the advancement of molecular artificial intelligence in a practical manner. The MolData benchmark data is available at https://GitHub.com/Transilico/MolData as well as within the additional files.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.